Publications

Journal Article
Research Support, Non-U.S. Gov't
Epublish 129 citations
Electronic publication date
October 1, 2019

View on Pubmed.gov 30140269 | View on doi.org 10.3389/fimmu.2...

Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.

Search for publications in this journal Front Immunol

  • Arum Park

    Search for this expert
    1
  • Yunhee Lee

    Search for this expert
    2
  • Mi Sun Kim

    Search for this expert
    3
  • Young Ju Kang

    Search for this expert
    4
  • Young-Jun Park

    Search for this expert
    1
  • Haiyoung Jung

    Search for this expert
    1
  • Tae-Don Kim

    Search for this expert
    1
  • Hee Gu Lee

    Search for this expert
    1
  • Inpyo Choi

    Search for this expert
    1
  • Suk Ran Yoon

    Search for this expert
    1

Abstract

Natural killer (NK) cells play important roles in immune surveillance. However, the tumor microenvironment suppresses NK cell function and allows cancer cells to evade immune detection. In this study, we investigated whether the thyroid cancer cell microenvironment has this effect on NK cells. We found that prostaglandin (PG) E2 produced by thyroid cancer cells suppressed the cytolytic activity of NK cells by inhibiting the expression of the natural cytotoxicity receptors NKp44 and NKp30 and the death receptor tumor necrosis factor-related apoptosis-inducing ligand. PGE2 and cyclooxygenase-2 were highly expressed in thyroid cancer cells; moreover, anaplastic thyroid cancer cells released higher amounts of PGE2 than the papillary subtype, which was associated with suppression of NK cell-inducing nuclear factor-κB and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways PGE2 receptor (EP) 2 and EP4 expressed on the NK cell surface. In addition, PGE2 inhibited the functional maturation of NK cells and reduced their cytotoxicity against target cells. These results indicate that PGE2 promotes thyroid cancer progression by inhibiting NK cell maturation and cytotoxicity. Thus, therapeutic strategies that target PGE2 in thyroid cancer could potentiate the immune response and improve patient prognosis.

References

J Immunol. 2008 Mar 15;180(6):3739-45

Nat Immunol. 2005 Jul;6(7):722-9

Nat Rev Immunol. 2006 Nov;6(11):836-48

Clin Cancer Res. 2014 Nov 15;20(22):5733-44

Cited by 129 citations (total)

Journal Article Review

Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells.

Electronic publication date May 12, 2020

Search for publications in this journal Front Genet

Rowa Y Alhabbab

The term cancer stem cell (CSC) starts 25 years ago with the evidence that CSC is a subpopulation of tumor...

Journal Article Review

Lipid metabolism in cancer progression and therapeutic strategies.

Electronic publication date November 13, 2021

Search for publications in this journal MedComm (2020)

Yan Fu [...] Qiongzhu Dong et al.

Dysregulated lipid metabolism represents an important metabolic alteration in cancer. Fatty acids, cholesterol, and phospholipid are the three most prevalent...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances